Table 3.

Trials of radiotherapy omission in elderly early breast cancer patients

		Design			Age		Stage			ER/PR status		Axillary Surgery		Results LR
NSABP B-21 [18]		RCT			ANY		T1a-bN0					AD		8y 16% vs. 3%
Toronto-BC trial [19]		RCT			≥ 50		T1-2N0			NA		AD		8y 17.6% vs. 3.5%
CALGB 9343 [3]		RCT			≥ 70		T1N0			ER-positive		AD or AS		12y 9% vs. 2%
PRIME II [2]		RCT			≥ 65		T < 3 cm N0			ER/PR positive		AD or AS		10y 9.5% vs. 0.9%
ABCSG 8 A [20]		RCT (2 × 2. With without tamoxifen. With/without radiation)			Post-menopausal		T ≤ 3 cm N0			ER/PR positive		AD		10y 7% vs. 2%
BASO 2 [21]		RCT (2 × 2. With without tamoxifen. With/without radiation)			< 70		T1N0			ER/PR positive		AD or AS		5y 4% vs. 1%
Trials of radiotherapy omission in early breast cancer patients incorporating biomarkers
	Design		Age	Stage		ER/PR status		Axillary Surgery	Systemic treatment		Biomarker		Results LR
LUMINA [22]	Prospective Cohort		≥ 55	T1N0		ER/PR positive		SLNB or AD	Endocrine therapy		Ki67 ≤ 13.25%		5y 2.3%
IDEA [23]	Prospective Cohort		50–70	T1N0				SLNB or AD	Endocrine therapy		Oncotype RS ≤ 18		Completed accrual
PRECISION [24]	Prospective Cohort		50–75	T1N0		ER/PR positive		SLNB or AD	Endocrine therapy		PAM-50 low ROR		Completed accrual
UK PRIMETIME [25]	Prospective Cohort		≥ 60	T1N0		ER/PR positive		SLNB	Endocrine therapy		IHC4 + C		Completed accrual
EXPERT [26]	Phase 3 RCT		≥ 50	T1N0		ER/PR positive		SLNB or AD	Endocrine therapy		PAM-50 low ROR ≤ 60		recruiting
DEBRA [27]	Phase 3 RCT		50–70	T1N0		ER/PR positive		SLNB or AD	Endocrine therapy		Oncotype Rs ≤ 18		recruiting